FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290829905> ?p ?o ?g. }

• W4290829905 endingPage "153" @default.
• W4290829905 startingPage "142" @default.
• W4290829905 abstract "Targeted therapy against actionable variants has revolutionised the treatment landscape for non-small cell lung cancer (NSCLC). Approximately half of NSCLC adenocarcinomas have an actionable variant, making molecular testing a critical component of the diagnostic process to personalise therapeutic options, optimise clinical outcomes and minimise toxicity. Recently, genomic testing in England has undergone major changes with the introduction of Genomic Laboratory Hubs, designed to consolidate and enhance existing laboratory provision and deliver genomic testing as outlined in the National Genomic Test Directory. Similar changes are ongoing in Scotland, Wales and Northern Ireland. However, multiple challenges exist with current tissue acquisition procedures and the molecular testing pathway in the UK, including quantity and quality of available tissue, adequacy rates, test availability among genomic laboratories, turnaround times, multidisciplinary team communication, and limited guidance and standardisation. The COVID-19 pandemic has added an extra layer of complexity.Herein, we summarise best practice recommendations, based on expert opinion, to overcome existing challenges in the UK. The least invasive biopsy technique should be undertaken with the aim of acquiring the greatest quality and quantity of tissue. Use of sedation should be considered to improve patient experience. Rapid on-site evaluation may also be useful to help guide adequate sampling, and liquid biopsy may be beneficial in some instances. Sample processing should be appropriate to facilitate biomarker testing, in particular, next-generation sequencing for comprehensive genomic information. Steps to optimise tissue utilisation and turnaround times, such as planning of tissue usage, limiting immunohistochemistry, tumour enrichment, and reflex testing at diagnosis, should be implemented. Guidelines for tissue acquisition and sample processing may help to improve sample adequacy to perform downstream testing. Communication among genomic laboratories will help to standardise test availability across England and local auditing could identify further areas for optimisation, including ways to improve turnaround times and adequacy rates." @default.
• W4290829905 created "2022-08-12" @default.
• W4290829905 creator A5006521386 @default.
• W4290829905 creator A5016383297 @default.
• W4290829905 creator A5038736479 @default.
• W4290829905 creator A5044994551 @default.
• W4290829905 creator A5052360804 @default.
• W4290829905 creator A5068874700 @default.
• W4290829905 creator A5090932878 @default.
• W4290829905 date "2022-10-01" @default.
• W4290829905 modified "2023-10-17" @default.
• W4290829905 title "Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement" @default.
• W4290829905 cites W1741814857 @default.
• W4290829905 cites W1992162148 @default.
• W4290829905 cites W1996111914 @default.
• W4290829905 cites W2020056350 @default.
• W4290829905 cites W2098851483 @default.
• W4290829905 cites W2118272646 @default.
• W4290829905 cites W2122187088 @default.
• W4290829905 cites W2153655235 @default.
• W4290829905 cites W2226969643 @default.
• W4290829905 cites W2239287815 @default.
• W4290829905 cites W2305475210 @default.
• W4290829905 cites W2443564243 @default.
• W4290829905 cites W2508716485 @default.
• W4290829905 cites W2566465788 @default.
• W4290829905 cites W2594615942 @default.
• W4290829905 cites W2599352654 @default.
• W4290829905 cites W2617493545 @default.
• W4290829905 cites W2661673758 @default.
• W4290829905 cites W2740124839 @default.
• W4290829905 cites W2800224623 @default.
• W4290829905 cites W2805726641 @default.
• W4290829905 cites W2807519281 @default.
• W4290829905 cites W2884436734 @default.
• W4290829905 cites W2886790097 @default.
• W4290829905 cites W2890894948 @default.
• W4290829905 cites W2906412478 @default.
• W4290829905 cites W2946166987 @default.
• W4290829905 cites W2946670461 @default.
• W4290829905 cites W2947524967 @default.
• W4290829905 cites W2953804209 @default.
• W4290829905 cites W2956783201 @default.
• W4290829905 cites W3004781275 @default.
• W4290829905 cites W3008151329 @default.
• W4290829905 cites W3013058016 @default.
• W4290829905 cites W3024185395 @default.
• W4290829905 cites W3025801868 @default.
• W4290829905 cites W3025887918 @default.
• W4290829905 cites W3030836401 @default.
• W4290829905 cites W3035565775 @default.
• W4290829905 cites W3080458669 @default.
• W4290829905 cites W3081995241 @default.
• W4290829905 cites W3092539296 @default.
• W4290829905 cites W3096441735 @default.
• W4290829905 cites W3097964344 @default.
• W4290829905 cites W3124080655 @default.
• W4290829905 cites W3131498244 @default.
• W4290829905 cites W3132779881 @default.
• W4290829905 cites W3133890830 @default.
• W4290829905 cites W3153812142 @default.
• W4290829905 cites W3182048312 @default.
• W4290829905 cites W3193739664 @default.
• W4290829905 cites W3196090799 @default.
• W4290829905 cites W3198587100 @default.
• W4290829905 cites W3201152054 @default.
• W4290829905 cites W4200291557 @default.
• W4290829905 cites W4206935904 @default.
• W4290829905 cites W4211168330 @default.
• W4290829905 cites W4379164750 @default.
• W4290829905 cites W2025980263 @default.
• W4290829905 doi "https://doi.org/10.1016/j.lungcan.2022.08.003" @default.
• W4290829905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36099709" @default.
• W4290829905 hasPublicationYear "2022" @default.
• W4290829905 type Work @default.
• W4290829905 citedByCount "1" @default.
• W4290829905 crossrefType "journal-article" @default.
• W4290829905 hasAuthorship W4290829905A5006521386 @default.
• W4290829905 hasAuthorship W4290829905A5016383297 @default.
• W4290829905 hasAuthorship W4290829905A5038736479 @default.
• W4290829905 hasAuthorship W4290829905A5044994551 @default.
• W4290829905 hasAuthorship W4290829905A5052360804 @default.
• W4290829905 hasAuthorship W4290829905A5068874700 @default.
• W4290829905 hasAuthorship W4290829905A5090932878 @default.
• W4290829905 hasBestOaLocation W42908299051 @default.
• W4290829905 hasConcept C111919701 @default.
• W4290829905 hasConcept C142724271 @default.
• W4290829905 hasConcept C176553487 @default.
• W4290829905 hasConcept C41008148 @default.
• W4290829905 hasConcept C71924100 @default.
• W4290829905 hasConceptScore W4290829905C111919701 @default.
• W4290829905 hasConceptScore W4290829905C142724271 @default.
• W4290829905 hasConceptScore W4290829905C176553487 @default.
• W4290829905 hasConceptScore W4290829905C41008148 @default.
• W4290829905 hasConceptScore W4290829905C71924100 @default.
• W4290829905 hasLocation W42908299051 @default.
• W4290829905 hasLocation W42908299052 @default.
• W4290829905 hasOpenAccess W4290829905 @default.

• next